Hormone selectivity in thyroid hormone receptors

Richard L. Wagner, B. Russell Huber, Andrew K. Shiau, Alex Kelly, Suzana T. Cunha Lima, Thomas (Tom) Scanlan, James W. Apriletti, John D. Baxter, Brian L. West, Robert J. Fletterick

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Separate genes encode thyroid hormone receptor subtypes TRα (NR1A1) and TRβ (NR1A2). Products from each of these contribute to hormone action, but the subtypes differ in tissue distribution and physiological response. Compounds that discriminate between these subtypes in vivo may be useful in treating important medical problems such as obesity and hypercholesterolemia. We previously determined the crystal structure of the rat (r) TRα ligand-binding domain (LBD). In the present study, we determined the crystal structure of the rTRα LBD in a complex with an additional ligand, Triac (3,5, 3′-triiodothyroacetic acid), and two crystal structures of the human (h) TRβ receptor LBD in a complex with either Triac or a TRβ-selective compound, GC-1 [3,5-dimethyl-4-(4′-hydroy-3′-isopropylbenzyl)-phenoxy acetic acid]. The rTRα and hTRβ LBDs show close structural similarity. However, the hTRβ structures extend into the DNA-binding domain and allow definition of a structural "hinge" region of only three amino acids. The two TR subtypes differ in the loop between helices 1 and 3, which could affect both ligand recognition and the effects of ligand in binding coactivators and corepressors. The two subtypes also differ in a single amino acid residue in the hormone-binding pocket, Asn (TRβ) for Ser (TRα). Studies here with TRs in which the subtype-specific residue is exchanged suggest that most of the selectivity in binding derives from this amino acid difference. The flexibility of the polar region in the TRβ receptor, combined with differential recognition of the chemical group at the 1-carbon position, seems to stabilize the complex with GC-1 and contribute to itsβ-selectivity. These results suggest a strategy for development of subtype-specific compounds involving modifications of the ligand at the 1-position.

Original languageEnglish (US)
Pages (from-to)398-410
Number of pages13
JournalMolecular Endocrinology
Volume15
Issue number3
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Thyroid Hormone Receptors
Hormones
Ligands
Amino Acids
Cold Climate
Co-Repressor Proteins
Tissue Distribution
Hypercholesterolemia
Acetic Acid
Carbon
Obesity
DNA
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology, Diabetes and Metabolism

Cite this

Wagner, R. L., Huber, B. R., Shiau, A. K., Kelly, A., Cunha Lima, S. T., Scanlan, T. T., ... Fletterick, R. J. (2001). Hormone selectivity in thyroid hormone receptors. Molecular Endocrinology, 15(3), 398-410. https://doi.org/10.1210/me.15.3.398

Hormone selectivity in thyroid hormone receptors. / Wagner, Richard L.; Huber, B. Russell; Shiau, Andrew K.; Kelly, Alex; Cunha Lima, Suzana T.; Scanlan, Thomas (Tom); Apriletti, James W.; Baxter, John D.; West, Brian L.; Fletterick, Robert J.

In: Molecular Endocrinology, Vol. 15, No. 3, 2001, p. 398-410.

Research output: Contribution to journalArticle

Wagner, RL, Huber, BR, Shiau, AK, Kelly, A, Cunha Lima, ST, Scanlan, TT, Apriletti, JW, Baxter, JD, West, BL & Fletterick, RJ 2001, 'Hormone selectivity in thyroid hormone receptors', Molecular Endocrinology, vol. 15, no. 3, pp. 398-410. https://doi.org/10.1210/me.15.3.398
Wagner RL, Huber BR, Shiau AK, Kelly A, Cunha Lima ST, Scanlan TT et al. Hormone selectivity in thyroid hormone receptors. Molecular Endocrinology. 2001;15(3):398-410. https://doi.org/10.1210/me.15.3.398
Wagner, Richard L. ; Huber, B. Russell ; Shiau, Andrew K. ; Kelly, Alex ; Cunha Lima, Suzana T. ; Scanlan, Thomas (Tom) ; Apriletti, James W. ; Baxter, John D. ; West, Brian L. ; Fletterick, Robert J. / Hormone selectivity in thyroid hormone receptors. In: Molecular Endocrinology. 2001 ; Vol. 15, No. 3. pp. 398-410.
@article{e01c30858ef34ab797dea2310938bc66,
title = "Hormone selectivity in thyroid hormone receptors",
abstract = "Separate genes encode thyroid hormone receptor subtypes TRα (NR1A1) and TRβ (NR1A2). Products from each of these contribute to hormone action, but the subtypes differ in tissue distribution and physiological response. Compounds that discriminate between these subtypes in vivo may be useful in treating important medical problems such as obesity and hypercholesterolemia. We previously determined the crystal structure of the rat (r) TRα ligand-binding domain (LBD). In the present study, we determined the crystal structure of the rTRα LBD in a complex with an additional ligand, Triac (3,5, 3′-triiodothyroacetic acid), and two crystal structures of the human (h) TRβ receptor LBD in a complex with either Triac or a TRβ-selective compound, GC-1 [3,5-dimethyl-4-(4′-hydroy-3′-isopropylbenzyl)-phenoxy acetic acid]. The rTRα and hTRβ LBDs show close structural similarity. However, the hTRβ structures extend into the DNA-binding domain and allow definition of a structural {"}hinge{"} region of only three amino acids. The two TR subtypes differ in the loop between helices 1 and 3, which could affect both ligand recognition and the effects of ligand in binding coactivators and corepressors. The two subtypes also differ in a single amino acid residue in the hormone-binding pocket, Asn (TRβ) for Ser (TRα). Studies here with TRs in which the subtype-specific residue is exchanged suggest that most of the selectivity in binding derives from this amino acid difference. The flexibility of the polar region in the TRβ receptor, combined with differential recognition of the chemical group at the 1-carbon position, seems to stabilize the complex with GC-1 and contribute to itsβ-selectivity. These results suggest a strategy for development of subtype-specific compounds involving modifications of the ligand at the 1-position.",
author = "Wagner, {Richard L.} and Huber, {B. Russell} and Shiau, {Andrew K.} and Alex Kelly and {Cunha Lima}, {Suzana T.} and Scanlan, {Thomas (Tom)} and Apriletti, {James W.} and Baxter, {John D.} and West, {Brian L.} and Fletterick, {Robert J.}",
year = "2001",
doi = "10.1210/me.15.3.398",
language = "English (US)",
volume = "15",
pages = "398--410",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "3",

}

TY - JOUR

T1 - Hormone selectivity in thyroid hormone receptors

AU - Wagner, Richard L.

AU - Huber, B. Russell

AU - Shiau, Andrew K.

AU - Kelly, Alex

AU - Cunha Lima, Suzana T.

AU - Scanlan, Thomas (Tom)

AU - Apriletti, James W.

AU - Baxter, John D.

AU - West, Brian L.

AU - Fletterick, Robert J.

PY - 2001

Y1 - 2001

N2 - Separate genes encode thyroid hormone receptor subtypes TRα (NR1A1) and TRβ (NR1A2). Products from each of these contribute to hormone action, but the subtypes differ in tissue distribution and physiological response. Compounds that discriminate between these subtypes in vivo may be useful in treating important medical problems such as obesity and hypercholesterolemia. We previously determined the crystal structure of the rat (r) TRα ligand-binding domain (LBD). In the present study, we determined the crystal structure of the rTRα LBD in a complex with an additional ligand, Triac (3,5, 3′-triiodothyroacetic acid), and two crystal structures of the human (h) TRβ receptor LBD in a complex with either Triac or a TRβ-selective compound, GC-1 [3,5-dimethyl-4-(4′-hydroy-3′-isopropylbenzyl)-phenoxy acetic acid]. The rTRα and hTRβ LBDs show close structural similarity. However, the hTRβ structures extend into the DNA-binding domain and allow definition of a structural "hinge" region of only three amino acids. The two TR subtypes differ in the loop between helices 1 and 3, which could affect both ligand recognition and the effects of ligand in binding coactivators and corepressors. The two subtypes also differ in a single amino acid residue in the hormone-binding pocket, Asn (TRβ) for Ser (TRα). Studies here with TRs in which the subtype-specific residue is exchanged suggest that most of the selectivity in binding derives from this amino acid difference. The flexibility of the polar region in the TRβ receptor, combined with differential recognition of the chemical group at the 1-carbon position, seems to stabilize the complex with GC-1 and contribute to itsβ-selectivity. These results suggest a strategy for development of subtype-specific compounds involving modifications of the ligand at the 1-position.

AB - Separate genes encode thyroid hormone receptor subtypes TRα (NR1A1) and TRβ (NR1A2). Products from each of these contribute to hormone action, but the subtypes differ in tissue distribution and physiological response. Compounds that discriminate between these subtypes in vivo may be useful in treating important medical problems such as obesity and hypercholesterolemia. We previously determined the crystal structure of the rat (r) TRα ligand-binding domain (LBD). In the present study, we determined the crystal structure of the rTRα LBD in a complex with an additional ligand, Triac (3,5, 3′-triiodothyroacetic acid), and two crystal structures of the human (h) TRβ receptor LBD in a complex with either Triac or a TRβ-selective compound, GC-1 [3,5-dimethyl-4-(4′-hydroy-3′-isopropylbenzyl)-phenoxy acetic acid]. The rTRα and hTRβ LBDs show close structural similarity. However, the hTRβ structures extend into the DNA-binding domain and allow definition of a structural "hinge" region of only three amino acids. The two TR subtypes differ in the loop between helices 1 and 3, which could affect both ligand recognition and the effects of ligand in binding coactivators and corepressors. The two subtypes also differ in a single amino acid residue in the hormone-binding pocket, Asn (TRβ) for Ser (TRα). Studies here with TRs in which the subtype-specific residue is exchanged suggest that most of the selectivity in binding derives from this amino acid difference. The flexibility of the polar region in the TRβ receptor, combined with differential recognition of the chemical group at the 1-carbon position, seems to stabilize the complex with GC-1 and contribute to itsβ-selectivity. These results suggest a strategy for development of subtype-specific compounds involving modifications of the ligand at the 1-position.

UR - http://www.scopus.com/inward/record.url?scp=17744379363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744379363&partnerID=8YFLogxK

U2 - 10.1210/me.15.3.398

DO - 10.1210/me.15.3.398

M3 - Article

C2 - 11222741

AN - SCOPUS:17744379363

VL - 15

SP - 398

EP - 410

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 3

ER -